SERMONIX NEW LOGO JPEG (2).jpg
Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape on April 22, 2024
19 avr. 2024 16h26 HE | Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, April 19, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic...
Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates of Harvard Medical School to advance clinical-stage neuroscience research
26 mars 2024 08h00 HE | Healis Therapeutics
The collaboration will focus on Healis’ clinical program studying the safety and efficacy of CKDB-501A, a BoNT/A neuromodulator, for neuropsychiatry.
Logo.png
Dr. Maurizio Fava of Massachusetts General Hospital to Serve as Principal Investigator for PT00114 Clinical Trial
16 déc. 2020 09h15 HE | Protagenic Therapeutics, Inc.
Clinical Trials of First-in-Class Peptide to Commence in 1H 2021 NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (OTCQB: PTIX) announced today that Dr. Maurizio Fava,...
FluoroPharma Medical, Inc..png
FPMI Restructures CardioPET License With Massachusetts General Hospital
27 sept. 2018 09h00 HE | FluoroPharma Medical, Inc.
MONTCLAIR, NJ, Sept. 27, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- FluoroPharma Medical Inc. (OTCQB: FPMI) announced today that it has reached an agreement with The General Hospital Corporation,...
National Brain Tumor Society 2017 Scientific Summit Showcases Research & Treatment Development Opportunities in Neuro-Oncology Field
31 oct. 2017 15h29 HE | National Brain Tumor Society
BOSTON, MA--(Marketwired - October 31, 2017) - National Brain Tumor Society (NBTS), the largest nonprofit dedicated to the brain tumor community in the United States, recently hosted its annual...
Editas-Logo-Small (1).jpg
Editas Medicine Announces Exclusive License to Advanced CRISPR Genome Editing Technology from Massachusetts General Hospital
03 août 2016 08h00 HE | Editas Medicine
-- License to Engineered Forms of Cas9 Nuclease Includes High-Fidelity Cas9 and Cas9 PAM Variants -- CAMBRIDGE, Mass., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a...
Vocera to Showcase E
Vocera to Showcase Enterprise Solutions for Communication and Collaboration at HIMSS16
18 févr. 2016 08h00 HE | Vocera Communications
SAN JOSE, Calif., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Vocera Communications, Inc. (NYSE:VCRA), the leading healthcare communications company, will showcase the Vocera Communication Platform at the...
Massachusetts Genera
Massachusetts General Hospital Improves Communication in Its Operating Rooms With Vocera
09 déc. 2015 08h00 HE | Vocera Communications
SAN JOSE, Calif., Dec. 09, 2015 (GLOBE NEWSWIRE) -- Vocera Communications (NYSE:VCRA), the leading mobile healthcare communications company, announced today that Massachusetts General Hospital (MGH)...